Cytokinetics (CYTK) News Today $44.55 -2.02 (-4.34%) Closing price 04:00 PM EasternExtended Trading$45.42 +0.87 (+1.95%) As of 07:39 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more. Add Compare Share Share Headlines Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestSustainabilityTrendsBuy This Stock All Sources Trusted Sources MarketBeat Benzinga Bloomberg GuruFocus MarketWatch Motley Fool NASDAQ PR Newswire Reuters Seeking Alpha TalkMarkets The Street TipRanks The Wall Street Journal Wall Street Zen Yahoo Finance Source Sentiment refers to the positivity or negativity of each headline according to our language processing algorithm. Sentiment All Sentiments Very Positive Positive Neutral Negative Very Negative Most Recent March 2025 February 2025 January 2025 December 2024 November 2024 October 2024 September 2024 August 2024 July 2024 June 2024 May 2024 April 2024 March 2024 February 2024 January 2024 December 2023 November 2023 October 2023 September 2023 August 2023 July 2023 June 2023 May 2023 April 2023 March 2023 February 2023 January 2023 December 2022 November 2022 October 2022 September 2022 August 2022 July 2022 June 2022 May 2022 April 2022 Time Period Is Cytokinetics, Incorporated (CYTK) a Promising Biotech Stock According to Wall Street AnalystsMarch 25 at 8:25 PM | msn.comCibc World Markets Corp Acquires New Holdings in Cytokinetics, Incorporated (NASDAQ:CYTK)Cibc World Markets Corp acquired a new stake in Cytokinetics, Incorporated (NASDAQ:CYTK - Free Report) in the fourth quarter, according to the company in its most recent filing with the SEC. The firm acquired 10,696 shares of the biopharmaceutical company's stock, valued at approximately $503,000.March 23 at 3:52 AM | marketbeat.comCytokinetics (NASDAQ:CYTK) Trading Up 4.9% - Here's WhyCytokinetics (NASDAQ:CYTK) Trading 4.9% Higher - Here's What HappenedMarch 22 at 12:32 PM | marketbeat.comIntech Investment Management LLC Purchases 17,602 Shares of Cytokinetics, Incorporated (NASDAQ:CYTK)Intech Investment Management LLC boosted its position in Cytokinetics, Incorporated (NASDAQ:CYTK - Free Report) by 53.9% during the 4th quarter, according to the company in its most recent Form 13F filing with the SEC. The institutional investor owned 50,273 shares of the biopharmaceutical companyMarch 22 at 4:44 AM | marketbeat.comVictory Capital Management Inc. Has $1.02 Million Stock Position in Cytokinetics, Incorporated (NASDAQ:CYTK)Victory Capital Management Inc. reduced its stake in shares of Cytokinetics, Incorporated (NASDAQ:CYTK - Free Report) by 39.0% during the 4th quarter, according to its most recent 13F filing with the SEC. The firm owned 21,716 shares of the biopharmaceutical company's stock after selling 13,888 shaMarch 21, 2025 | marketbeat.comCytokinetics, Incorporated (NASDAQ:CYTK) Receives $82.00 Average PT from BrokeragesMarch 21, 2025 | americanbankingnews.comCytokinetics announces launch of EARTH-HCMMarch 20, 2025 | markets.businessinsider.comCytokinetics Announces Launch of EARTH-HCM, a Public Health Education Tool for the Hypertrophic Cardiomyopathy CommunityMarch 20, 2025 | globenewswire.comInsider Selling: Cytokinetics, Incorporated (NASDAQ:CYTK) EVP Sells 2,775 Shares of StockCytokinetics, Incorporated (NASDAQ:CYTK - Get Free Report) EVP Andrew Callos sold 2,775 shares of the firm's stock in a transaction that occurred on Monday, March 17th. The shares were sold at an average price of $44.38, for a total transaction of $123,154.50. Following the completion of the transaction, the executive vice president now directly owns 34,888 shares in the company, valued at approximately $1,548,329.44. The trade was a 7.37 % decrease in their ownership of the stock. The sale was disclosed in a legal filing with the SEC, which is accessible through the SEC website.March 18, 2025 | marketbeat.comRobert I. Blum Sells 12,648 Shares of Cytokinetics, Incorporated (NASDAQ:CYTK) StockCytokinetics, Incorporated (NASDAQ:CYTK - Get Free Report) CEO Robert I. Blum sold 12,648 shares of the stock in a transaction dated Monday, March 17th. The shares were sold at an average price of $44.38, for a total transaction of $561,318.24. Following the sale, the chief executive officer now directly owns 326,533 shares in the company, valued at $14,491,534.54. This trade represents a 3.73 % decrease in their ownership of the stock. The sale was disclosed in a legal filing with the SEC, which is available through the SEC website.March 18, 2025 | marketbeat.comCytokinetics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)March 18, 2025 | globenewswire.comAndrew Callos Sells 2,775 Shares of Cytokinetics, Incorporated (NASDAQ:CYTK) StockMarch 18, 2025 | insidertrades.comCytokinetics, Incorporated (NASDAQ:CYTK) Receives Average Rating of "Moderate Buy" from BrokeragesShares of Cytokinetics, Incorporated (NASDAQ:CYTK - Get Free Report) have been assigned an average rating of "Moderate Buy" from the eighteen research firms that are presently covering the company, Marketbeat.com reports. Two analysts have rated the stock with a hold recommendation, fifteen have isMarch 18, 2025 | marketbeat.comCytokinetics’ data supports aficamten’s potential, says H.C. WainwrightMarch 18, 2025 | markets.businessinsider.comCytokinetics: Derisked PDUFA Ahead, But Commercial Success Is The QuestionMarch 17, 2025 | seekingalpha.comCytokinetics announces presentations as ACC Scientific Session & ExpoMarch 17, 2025 | markets.businessinsider.comCytokinetics Announces Five Presentations at the American College of Cardiology Annual Scientific Session & ExpoMarch 17, 2025 | globenewswire.comCytokinetics Nears Approval: 'Buy' The New Potential Cardiology Franchise With AficamtenMarch 16, 2025 | seekingalpha.comSkandinaviska Enskilda Banken AB publ Has $8.59 Million Holdings in Cytokinetics, Incorporated (NASDAQ:CYTK)Skandinaviska Enskilda Banken AB publ increased its stake in Cytokinetics, Incorporated (NASDAQ:CYTK - Free Report) by 16.9% in the 4th quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission. The fund owned 182,126 shares of the biopharmaceuticalMarch 16, 2025 | marketbeat.comGreat Lakes Advisors LLC Invests $1.58 Million in Cytokinetics, Incorporated (NASDAQ:CYTK)Great Lakes Advisors LLC bought a new position in shares of Cytokinetics, Incorporated (NASDAQ:CYTK - Free Report) during the 4th quarter, according to its most recent disclosure with the Securities & Exchange Commission. The firm bought 33,589 shares of the biopharmaceutical company's stock, vMarch 16, 2025 | marketbeat.comCharles Schwab Investment Management Inc. Raises Stake in Cytokinetics, Incorporated (NASDAQ:CYTK)Charles Schwab Investment Management Inc. lifted its position in shares of Cytokinetics, Incorporated (NASDAQ:CYTK - Free Report) by 1.0% in the fourth quarter, according to its most recent 13F filing with the SEC. The firm owned 1,335,189 shares of the biopharmaceutical company's stock after purchMarch 13, 2025 | marketbeat.comCytokinetics says FDA does not plan advisory committee meeting for aficamten NDAMarch 10, 2025 | markets.businessinsider.comCytokinetics, Incorporated (NASDAQ:CYTK) EVP Sells $144,565.07 in StockCytokinetics, Incorporated (NASDAQ:CYTK - Get Free Report) EVP Andrew Callos sold 3,341 shares of Cytokinetics stock in a transaction dated Thursday, March 6th. The shares were sold at an average price of $43.27, for a total transaction of $144,565.07. Following the sale, the executive vice president now owns 64,434 shares in the company, valued at approximately $2,788,059.18. This represents a 4.93 % decrease in their ownership of the stock. The sale was disclosed in a filing with the Securities & Exchange Commission, which is available at this hyperlink.March 8, 2025 | marketbeat.comInsider Selling: Cytokinetics, Incorporated (NASDAQ:CYTK) CEO Sells 16,970 Shares of StockCytokinetics, Incorporated (NASDAQ:CYTK - Get Free Report) CEO Robert I. Blum sold 16,970 shares of the business's stock in a transaction on Thursday, March 6th. The shares were sold at an average price of $43.44, for a total transaction of $737,176.80. Following the sale, the chief executive officer now directly owns 364,181 shares in the company, valued at $15,820,022.64. The trade was a 4.45 % decrease in their position. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through the SEC website.March 8, 2025 | marketbeat.comB. Riley Analysts Reduce Earnings Estimates for CytokineticsCytokinetics, Incorporated (NASDAQ:CYTK - Free Report) - Equities researchers at B. Riley reduced their FY2025 EPS estimates for shares of Cytokinetics in a research note issued on Wednesday, March 5th. B. Riley analyst M. Mamtani now forecasts that the biopharmaceutical company will post earningMarch 8, 2025 | marketbeat.comAndrew Callos Sells 3,341 Shares of Cytokinetics, Incorporated (NASDAQ:CYTK) StockMarch 8, 2025 | insidertrades.comCytokinetics (CYTK) Receives a New Rating from Morgan StanleyMarch 7, 2025 | markets.businessinsider.comWhat is B. Riley's Estimate for Cytokinetics Q1 Earnings?Cytokinetics, Incorporated (NASDAQ:CYTK - Free Report) - Investment analysts at B. Riley issued their Q1 2025 EPS estimates for shares of Cytokinetics in a report issued on Wednesday, March 5th. B. Riley analyst M. Mamtani anticipates that the biopharmaceutical company will post earnings of ($1.4March 7, 2025 | marketbeat.comRevenue Downgrade: Here's What Analysts Forecast For Cytokinetics, Incorporated (NASDAQ:CYTK)March 5, 2025 | finance.yahoo.comB.Riley Financial Reaffirms Their Buy Rating on Cytokinetics (CYTK)March 5, 2025 | markets.businessinsider.comInsider Sell: Andrew Callos Sells Shares of Cytokinetics Inc (CYTK)March 5, 2025 | gurufocus.comInsider Sell Alert: Fady Malik Sells Shares of Cytokinetics Inc (CYTK)March 5, 2025 | gurufocus.comCytokinetics (CYTK) Gets a Buy from Truist FinancialMarch 3, 2025 | markets.businessinsider.comCytokinetics to Participate in March Investor ConferencesMarch 3, 2025 | globenewswire.comCytokinetics, Incorporated (NASDAQ:CYTK) Shares Sold by Silphium Asset Management LtdSilphium Asset Management Ltd reduced its stake in shares of Cytokinetics, Incorporated (NASDAQ:CYTK - Free Report) by 59.2% during the 4th quarter, according to its most recent filing with the SEC. The firm owned 30,000 shares of the biopharmaceutical company's stock after selling 43,564 shares duMarch 3, 2025 | marketbeat.comCytokinetics, Incorporated (NASDAQ:CYTK) Shares Bought by Fisher Asset Management LLCFisher Asset Management LLC lifted its stake in Cytokinetics, Incorporated (NASDAQ:CYTK - Free Report) by 13.7% in the fourth quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission. The firm owned 616,492 shares of the biopharmaceutical company'sMarch 3, 2025 | marketbeat.comBrokers Set Expectations for Cytokinetics Q1 EarningsCytokinetics, Incorporated (NASDAQ:CYTK - Free Report) - Stock analysts at HC Wainwright issued their Q1 2025 EPS estimates for shares of Cytokinetics in a report released on Friday, February 28th. HC Wainwright analyst J. Pantginis anticipates that the biopharmaceutical company will post earningMarch 3, 2025 | marketbeat.comCytokinetics (NASDAQ:CYTK) Shares Gap Down - Here's What HappenedCytokinetics (NASDAQ:CYTK) Shares Gap Down - Should You Sell?March 1, 2025 | marketbeat.comHC Wainwright Reaffirms Buy Rating for Cytokinetics (NASDAQ:CYTK)HC Wainwright reaffirmed a "buy" rating and set a $120.00 price target on shares of Cytokinetics in a research report on Friday.March 1, 2025 | marketbeat.comSmart Money Is Betting Big In CYTK OptionsMarch 1, 2025 | benzinga.comCytokinetics (NASDAQ:CYTK) Issues Earnings ResultsCytokinetics (NASDAQ:CYTK - Get Free Report) announced its earnings results on Thursday. The biopharmaceutical company reported ($1.26) earnings per share (EPS) for the quarter, beating the consensus estimate of ($1.29) by $0.03.February 28, 2025 | marketbeat.comStifel Nicolaus Remains a Buy on Cytokinetics (CYTK)February 28, 2025 | markets.businessinsider.comCytokinetics (CYTK) Gets a Buy from Piper SandlerFebruary 28, 2025 | markets.businessinsider.comCytokinetics Inc (CYTK) Q4 2024 Earnings Call Highlights: Revenue Surge Amidst Rising ExpensesFebruary 28, 2025 | finance.yahoo.comDecoding Cytokinetics Inc (CYTK): A Strategic SWOT InsightFebruary 28, 2025 | gurufocus.comQ4 2024 Cytokinetics Inc Earnings Call TranscriptFebruary 28, 2025 | gurufocus.comCytokinetics, Incorporated (CYTK) Q4 2024 Earnings Call TranscriptFebruary 27, 2025 | seekingalpha.comCytokinetics reports Q4 EPS ($1.26), consensus ($1.17)February 27, 2025 | markets.businessinsider.comCytokinetics files automatic mixed securities shelfFebruary 27, 2025 | markets.businessinsider.comCytokinetics Inc (CYTK) Reports 2024 Financial Results and 2025 OutlookFebruary 27, 2025 | gurufocus.com Remove Ads Get Cytokinetics News Delivered to You Automatically Sign up to receive the latest news and ratings for CYTK and its competitors with MarketBeat's FREE daily newsletter. Email Address CYTK Media Mentions By Week CYTK Media Sentiment Learn about the media sentiment score. Each headline receives a score ranging from 2 (good news) to -2 (bad news). Our company news sentiment scores track the average news sentiment of articles about each company over the most recent 7 days in order to identify companies that are receiving positive press. CYTK News Sentiment▼0.540.63▲Average Medical News Sentiment CYTK News Coverage Learn about the media coverage comparison. We track news headlines from hundreds of news outlets and tag them by company. This chart compares the number of articles about this company in the last seven days compared with the average number of articles about this company on a typical week. CYTK Articles This Week▼109▲CYTK Articles Average Week Remove Ads Get Cytokinetics News Delivered to You Automatically Sign up to receive the latest news and ratings for CYTK and its competitors with MarketBeat's FREE daily newsletter. Email Address Related Companies and Tools Related Companies Teva Pharmaceutical Industries News Summit Therapeutics News Intra-Cellular Therapies News Moderna News Genmab A/S News Dr. Reddy's Laboratories News Viatris News Ascendis Pharma A/S News Vaxcyte News Qiagen News Headlines Tools Trending Media MentionsHigh Media Sentiment StocksLive News FeedMarketBeat OriginalsStock Ideas This page (NASDAQ:CYTK) was last updated on 3/25/2025 by MarketBeat.com Staff From Our PartnersYour Wealth is Under AttackPlease don't wait—this is your moment to take action. Download your Wealth Protection Guide now, claim your fr...American Alternative | SponsoredA brutally honest economic warning for 2025 (see proof)New York Times best-selling financial author and world-renowned economist Addison Wiggin (a man who’s worked s...Banyan Hill Publishing | Sponsored$2 Trillion Disappears Because of Fed's Secretive New Move$2 trillion has disappeared from the US government's books. The reason why is a new, secretive move being c...Stansberry Research | SponsoredHas Trump finally met his match?Dylan Jovine predicted the 2008 crash over a year before it happened. Folks who listened to him had the chance...Behind the Markets | SponsoredCollect $7k per month from Tesla’s SECRET dividendTesla doesn't pay a traditional dividend.... But I just discovered a secret backdoor to collect a secret 69...Investors Alley | SponsoredDOGE officially begins retirement transformationElon Musk's Department of Government Efficiency ("DOGE") just announced the first-ever "fully digital retireme...Altimetry | Sponsored“Amazon Coin” set to outperform BitcoinChris Rowe – the man who recommended Amazon in 1998… Bitcoin and Ethereum in 2017… And has spotted 44 diffe...True Market Insiders | SponsoredEx CIA predicts 40% “double crash” – April 11The scientists here don’t study deadly viruses… directed energy weapons… or even weather control technology… ...Paradigm Press | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Cytokinetics, Incorporated Please log in to your account or sign up in order to add this asset to your watchlist. Share Cytokinetics With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
Buy CYTK Stock Free CYTK Stock Alerts